November 8, 2013

Danisco Animal Nutrition receives FDA approval for phytase for swine

Following the launch of its patented bacterial phytase Axtra^® PHY to the poultry sector earlier this year, DuPont subsidiary Danisco Animal Nutrition has received FDA approval for a lower Axtra^® PHY dose level for swine  at 250 FTU/kg of feed.

Axtra^® PHY offers cost-effective dosing through the use of a strong set of matrix values which are supported by numerous worldwide trials at different production stages (weaner and grower/finisher). It is also more bio-efficacious than E.coli phytases.

It offers additional cost savings of about US$1.08 per tonne (about US$0.98 per short ton) of pig feed through its ability to make available about 20% more phosphorus and calcium earlier in the digestive process. It also provides about 10% increased availability of digestible energy to the pig through superior phytate degradation in the upper gut.  Lastly, without the need for manure management, it allows further costs savings.

Axtra^® PHY is available in liquid and dry product forms. If a dry product form is preferred, maximum performance and ease of use is ensured through its Thermo Protection Technology (TPT) granule, ensuring heat stability of up to 203°F (95°C).

Axtra^® PHY benefits from strong support services, such as a FASTKit^® assay which detects the presence of active Axtra^® PHY in feed and a new online service, Optimize Feed™, which helps producers optimise diet formulation to ensure maximum cost savings.

Gwendolyn Jones, technical services manager at Danisco Animal Nutrition commented, "Pig producers are facing tough times because of market and feed cost volatility so anything that can save them buying more product than they need to achieve profitable results has to be good news. Axtra^® PHY is the most advanced phytase technology on the market and its cost effectiveness at low dose is backed with solid, evidence based matrix values."